CSI Market
Sign In | Register

Cytosorbents (CTSO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CTSO Annual Cash Flow →
Cash flow data covering Cytosorbents–Jun 30 2025 offers a view into how Jun 30 2026's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-9.55
Depreciation & amortization1.18
Amortization of Other Assets0.70
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived0.65
Provision For Loan Losses Expensed0.24
Increase (Decrease) in Inventories-1.51
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.11
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized-2.14
Technology And Content Expense-
Consulting Fees-
Service Management Costs-
Change In Fair Value Of Management Units-
Conversion Of Stock Amount Issued-
Supplemental Noncash Transations-
Preferred Dividends Accrued Not Yet Paid-
Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest-
Issuance Of Stocks And Warrants For Services Or Claims-
Accrued Final Fee-
Non Cash Restricted Stock Unit Compensation-
Amortization Of Loan Costs-
Operating Lease Right Of Use Asset Amortization Expense0.03
Tangible Asset Impairment Charges-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.38
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.31
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.65
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities8.29
Discontinued operations0.00
Net Cash flow from Operating Activities-1.75
Investing Activities
Capital Expenditures-0.12
Sale of Capital Items0.09
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.04
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments Of Debt Issuance Cost-
Payment Of Non Refundable Final Fee Upon Termination Or Maturity Of Debt Instrument-
Proceeds From Repayments Of Equity-
Payments For Equity Contributions Net Of Fees Incurred-
Payments Of Final Fees-
Sale Of Stock Consideration Received On Transaction-
Net Proceeds From Issuance Rights Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.05
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.78
Total Cash Flow-1.84
4 historic quarters locked

Sign in to unlock the full Cytosorbents cash flow history.

Sign In Create Free Account

About Cytosorbents Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-092006

Figures are derived from filed reports and may be restated. Historical data is subject to revision.